Ex Vivo T-celdepletie van gemobiliseerde perifere bloedstamcellen via CD34-selectie (EXCESS)
Ex Vivo T-celdepletie van gemobiliseerde perifere bloedstamcellen via CD34-selectie (EXCESS)
Participants are being asked to take part in this study because treatment of his or her disease requires a stem cell transplant. Stem cells or "mother" cells are the source of normal blood cells and lead to recovery of blood counts after bone marrow transplantation. Unfortunately, there is not a perfectly matched stem cell donor (like a sister or brother) for the participant and his or her disease does not permit enough time to identify another donor (like someone from a registry list that is not his or her relative) or another suitable donor has not been identified. However, a close relative of the patient has been identified whose stem cells are not a perfect match, but can be used.
Alternatively, the patient may have already received a stem cell transplant but have evidence of mixed chimerism, which means some of the patient's own bone marrow cells are present, rather than all of the donor's cells. This may lead to an increased risk of the disease coming back. Or, the patient may have all donor cells but his or her bone marrow is not working very well, which may lead to frequent blood or platelet (cells that help in clotting blood) transfusions or infection.
Regardless of the reason, it may be necessary to isolate stem cells from a haploidentical (half-match) donor in order to provide bone marrow function. Because the stem cells from the donor are only half-matched to the participant, the risk of graft-versus-host disease (GvHD) is very high. GvHD is a complication after transplant caused by donor T cells (graft) that attack the transplant recipient, and this complication can cause death after transplant. Thus, it is important that the donor's blood cells are treated to minimize cells that are most likely to attack the host's tissues. This is done by using a special device to capture the CD34+ stem cells from the donor's stem cell product prior to giving the cells to the host. This method minimizes the donor T cells, which are responsible for causing GvHD.
Purpose: In an effort to lower the occurrences and severity of graft-versus-host disease in patients and to lower the rate of transplant failure, investigators would like to specially treat the donor's blood cells to minimize the cells that are most likely to attack the patient's tissues.
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Gedetailleerde beschrijving
Participation in this project will last approximately one year with follow-up exams.
Before treatment can begin, stem cells will be collected from the donor (a close relative) that has been selected as the best match for the participant. White blood cells will be collected from the donor. The cells will then be mixed with a special protein, called a CD34 antibody, that binds to the stem cells, which will then be separated out from the white blood cells by a special machine- called a CliniMACS CD34 Reagent System in the laboratory. This is an investigational device that is not approved by the FDA. Although this device is not approved for use in this country, it has been in use for years and is approved in other countries. The stem cells will be collected and given fresh or they can be frozen before they will be given to the participant.
On about days 28, 60, 100, 180 and 365 after the transplant, the participant will have the same tests/evaluations since the time of transplant. For patients who do not develop GvHD, they are not required to have these tests/evaluations.
In addition, for purposes of the study, health-related information will be collected for a year from the time of stem cell infusion. This will be used to determine survival, relapse, infections and GvHD that may occur following transplant.
Studietype
Studietype
Inschrijving (Geschat)
Inschrijving
Fase
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
Studiecontact
- Naam: Marlen Dinu
- Telefoonnummer: 832-824-4881
- E-mail: mxdinu@txch.org
Studie Contact Back-up
- Naam: Robert Krance, MD
- Telefoonnummer: 832-824-4661
- E-mail: rakrance@txch.org
Studie Locaties
-
-
Texas
-
Houston, Texas, Verenigde Staten, 77030
- Werving
- Houston Methodist Hospital
-
Contact:
- Marlen Dinu
- Telefoonnummer: 832-824-4881
- E-mail: mxdinu@txch.org
-
Contact:
- Robert Krance, MD
- Telefoonnummer: 832-824-4661
- E-mail: rakrance@txch.org
-
Houston, Texas, Verenigde Staten, 77030
- Werving
- Texas Children's Hospital
-
Contact:
- Marlen Dinu
- Telefoonnummer: 832-824-4881
- E-mail: mxdinu@txch.org
-
Contact:
- Robert Krance, MD
- Telefoonnummer: 832-824-4661
- E-mail: rakrance@txch.org
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion criteria for Stem Cell Transplant WITH Conditioning (COHORT 1)
- Patient requiring allogeneic SCT
- Age between birth and 70 years
- Patient and/or responsible person able to understand and sign consent
Exclusion criteria for Stem Cell Transplant WITH Conditioning (COHORT 1)
- Active, acute GvHD > grade II or extensive, chronic GvHD
- Severe life, threatening infection
- Pulmonary dysfunction (FEV1, FVC or DLCO 40% of predicted or 3 SD below normal)
- Cardiac dysfunction (LVSF less than 25%)
- Psychiatric disturbance
- Lansky or Karnofsky score < 50%
- The presence of severe hepatic disease (direct bilirubin >3x upper limit of normal and AST > 5x upper limit of normal).
- Creatinine > 3x normal
- Known HIV Positivity
- Pregnancy
Inclusion Criteria for CD34+ Topoff WITHOUT conditioning (COHORT 2)
-
Allogeneic SCT Recipient requiring additional cellular therapy
-
Age between birth and 70 years
-
Patient and/or responsible person able to understand and sign consent
-
At least ONE of the following must be answered YES for a patient to be eligible to receive CD34+ topoff:
- Evidence of mixed chimerisms (less than 95% donor cells)
- Evidence of poor bone marrow function (bone marrow cellularity less than 50% with at least one cytopenia)
- Relapsed or persistent disease
Exclusion criteria for CD34+ Topoff WITHOUT conditioning (COHORT 2)
- Active, acute GvHD > grade II or extensive, chronic GvHD
- Severe life, threatening infection
- Known HIV positivity
- Pregnancy
Inclusion Criteria for CD34+ Topoff WITH conditioning (COHORT 3)
-
Allogeneic SCT Recipient requiring additional cellular therapy
-
Age between birth and 70 years
-
Patient and/or responsible person able to understand and sign consent
-
At least ONE of the following must be answered YES for a patient to be eligible to receive CD34+ topoff:
- Evidence of mixed chimerisms (less than 95% donor cells)
- Evidence of poor bone marrow function (bone marrow cellularity less than 50% with at least one cytopenia)
- Relapsed or persistent disease
Exclusion criteria for CD34+ Topoff WITH Conditioning (COHORT 3)
- Active, acute GVHD > grade II or extensive, chronic GvHD
- Severe life, threatening infection
- Pulmonary disfunction (FEV1, FVC or DLCO 40% of predicted or 3 SD below normal)
- Cardiac dysfunction (LVSF less than 25%)
- Psychiatric disturbance
- Lansky or Karnofsky score < 50%
- The presence of severe hepatic disease (direct bilirubin > 3x upper limit of normal and AST > 5x upper limit of normal)
- Creatinine > 3x normal
- Known HIV positivity
- Pregnancy
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Experimenteel: Cohort 2: CD34+ cells as a top off Without Conditioning
Cohort 2 consists of patients needing additional CD34+ stem cells collected by 'CliniMACS CD34 Reagent system' as a "topoff" without the need for additional conditioning prior to the infusion. These patients who have already received SCT and are receiving CD34+ cells from their original donor for poor graft function, declining chimerism or disease relapse. |
A special machine that separates out the donor cells that have been mixed with a special protein, CD34 antibody, that binds to the stem cells from the white blood cells. |
|
Experimenteel: Cohort 1: CD34+ Cells for transplant
Cohort 1 consists of patients receiving CD34+ selected peripheral blood stem cell transplant with a preceding conditioning regimen (chemotherapy with, or without, radiation). The stem cells will then be separated out from the white blood cells by a special machine- called a CliniMACS CD34 Reagent System in the laboratory. |
A special machine that separates out the donor cells that have been mixed with a special protein, CD34 antibody, that binds to the stem cells from the white blood cells. |
|
Experimenteel: Cohort 3: CD34+ cells as a top off With Conditioning
Cohort 3 consists of patients needing additional CD34+ stem cells collected by 'CliniMACS CD 34+ Reagent System' as a "topoff" with the need for additional conditioning prior to the infusion. These patients who have already received SCT with conditioning and are receiving CD34+ cells from their original donor for poor graft function, declining chimerism or disease relapse. |
A special machine that separates out the donor cells that have been mixed with a special protein, CD34 antibody, that binds to the stem cells from the white blood cells. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
For Cohort 1: the rate of primary engraftment 50 days post SCT
Tijdsspanne: 50 days
|
Primary engraftment is defined as achievement of absolute neutrophil count (ANC) is greater than or equal to 500/ul for three consecutive days by day 50 post transplant. The treatment regimen will be considered clinically useful if the primary engraftment rate is at least 85%. |
50 days
|
|
For Cohort 2 (Without Conditioning) and Cohort 3 (With Conditioning): The total incidence of overall acute GvHD (greater than or equal to grade 3)
Tijdsspanne: 100 days
|
The overall incidence of acute GvHD will be measured 100 days post stem cell transplant. The regimen will be considered acceptable if aGvHD greater than or equal to grade 3 rate is at least 10% or lower. |
100 days
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Assessment of Long Term Survival
Tijdsspanne: 1 year
|
Long term survival of recipients of G-CSF mobilized peripheral blood stem cells depleted of T cells by positive selection for the CD34+ antigen |
1 year
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Medewerkers
Medewerkers
Onderzoekers
Onderzoekers
- Hoofdonderzoeker: Robert Krance, MD, Baylor College of Medicine
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Studie start
Primaire voltooiing (Geschat)
Primaire voltooiing
Studie voltooiing (Geschat)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Geschat)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Andere studie-ID-nummers
Andere studie-ID-nummers
- H-27251 EXCESS
- EXCESS (Andere identificatie: Baylor College of Medicine)
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .